Sant'Anna, R., Almeida, M. R., Varejao, N., Gallego, P., et al. (2017). Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Scientific Reports, 7.

Ferreira, N., Gonçalves, N. P., Saraiva, M. J., & Almeida, M. R. (2016). Curcumin: A multi-Target disease-modifying agent for late-stage transthyretin amyloidosis. Scientific Reports, 6.

Simões, C. J. V., Almeida, Z. L., Costa, D., Jesus, C. S. H., et al. (2016). A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition. European Journal of Medicinal Chemistry, 121, 823 - 840.

Sant'Anna, R., Gallego, P., Robinson, L. Z., Pereira-Henriques, A., et al. (2016). Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nature Communications, 7.

Ferreira, N., Pereira-Henriques, A., & Almeida, M. R. (2015). Transthyretin chemical chaperoning by flavonoids: Structure-activity insights towards the design of potent amyloidosis inhibitors. Biochemistry and Biophysics Reports, 3, 123 - 133.

Ferreira, N., Santos, S. A. O., Domingues, M. R. M., Saraiva, M. J., & Almeida, M. R. (2013). Dietary curcumin counteracts extracellular transthyretin deposition: Insights on the mechanism of amyloid inhibition. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1832(1), 39 - 45.

Almeida, M. R., & Saraiva, M. J. (2012). Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin. FEBS Letters, 586(18), 2891 - 2896.

Ferreira, N., Saraiva, M. J., & Almeida, M. R. (2012). Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "In vivo" evidence from FAP mice models. PLoS ONE, 7(1).

Ferreira, N., Saraiva, M. J., & Almeida, M. R. (2012). Natural polyphenols as modulators of TTR amyloidogenesis: In vitro and in vivo evidences towards therapy. Amyloid, 19(SUPPL. 1), 39 - 42.

Saraiva, M. J., Magalhaes, J., Ferreira, N., & Almeida, M. R. (2012). Transthyretin deposition in familial amyloidotic polyneuropathy. Current Medicinal Chemistry, 19(15), 2304 - 2311.

Ferreira, N., Saraiva, M. J., & Almeida, M. R. (2011). Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Letters, 585(15), 2424 - 2430.

Pessoa, J., Sárkány, Z., Ferreira-Da-Silva, F., Martins, S., et al. (2010). Functional characterization of Arabidopsis thaliana transthyretin-like protein. BMC Plant Biology, 10.

Martinho, A., Gonçalves, I., Cardoso, I., Almeida, M. R., et al. (2010). Human metallothioneins 2 and 3 differentially affect amyloid-beta binding by transthyretin. FEBS Journal, 277(16), 3427 - 3436.

Ferreira, N., Cardoso, I., Domingues, M. R., Vitorino, R., et al. (2009). Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Letters, 583(22), 3569 - 3576.

Mairal, T., Nieto, J., Pinto, M., Almeida, M. R., et al. (2009). Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS ONE, 4(1).

Mairal, T., Nieto, J., Pinto, M., Almeida, M. R., et al. (2009). Iodine atoms: A new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS ONE, 4(1).

González, A., Quirante, J., Nieto, J., Almeida, M. R., et al. (2009). Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 19(17), 5270 - 5273.

Liz, M. A., Fleming, C. E., Nunes, A. F., Almeida, M. R., et al. (2009). Substrate specificity of transthyretin: Identification of natural substrates in the nervous system. Biochemical Journal, 419(2), 467 - 474.

Macedo, B., Batista, A. R., Ferreira, N., Almeida, M. R., & Saraiva, M. J. (2008). Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1782(9), 517 - 522.

Gales, L., Almeida, M. R., Arsequell, G., Valencia, G., et al. (2008). Iodination of salicylic acid improves its binding to transthyretin. Biochimica et Biophysica Acta - Proteins and Proteomics, 1784(3), 512 - 517.

Cardoso, I., Almeida, M. R., Ferreira, N., Arsequell, G., et al. (2007). Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: Relevance in drug design. Biochemical Journal, 408(1), 131 - 138.

Magalhães, V., Veiga-Malta, I., Almeida, M. R., Baptista, M., et al. (2007). Interaction with human plasminogen system turns on proteolytic activity in Streptococcus agalactiae and enhances its virulence in a mouse model. Microbes and Infection, 9(11), 1276 - 1284.

Almeida, M. R., Gales, L., Damas, A. M., Cardoso, I., & Saraiva, M. J. (2005). Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Current Drug Targets: CNS and Neurological Disorders, 4(5), 587 - 596.

Almeida, M. R., Macedo, B., Cardoso, I., Alves, I., et al. (2004). Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochemical Journal, 381(2), 351 - 356.